已收盘 10-02 16:00:00 美东时间
-0.010
-0.27%
Cartesian Therapeutics granted inducement awards to four new employees on October 1, 2026, offering options to purchase 121,900 shares at $7.22 per share. The options vest 25% on October 1, 2027, with monthly installments over three years, fully vesting by October 1, 2030, and have a 10-year term. The awards were approved by the board under the 2018 Employment Inducement Incentive Award Plan and comply with Nasdaq Rule 5635(c)(4).
10-02 11:00
OrthoPediatrics Corp. sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, which brought together a record 39 participants from 23 institutions across 22 cities and three countries. The event, held in Memphis, Tennessee, featured expert-led instruction, hands-on learning, and opportunities to connect within the pediatric orthopedic community. The course covered topics such as upper extremity trauma, hip and lower extremity t...
10-01 11:05
<p>AppFolio introduced new innovations at FUTU<em>RE</em>, expanding its Realm-X and Performance Platform. The new Realm-X enhances multi-step work handling, memory, knowledge base, skills, and prompt-to-flow/dashboard capabilities. It integrates with existing Performers, improving efficiency and outcomes for teams, residents, and investors. Key features include boosted showings, resolved work orders, and time savings. AppFolio also announced par...
09-29 16:00
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. According to the announcement, the agreement gives Tempest an exclusi...
09-16 17:04
ONEOK, Inc. announced the pricing terms of ONEOK, L.L.C.’s cash tender offers to purchase up to $2 billion in aggregate principal amount of its debt securities. The tender offers include early and regular tender considerations, with early tenders accepted at higher prices. The offers are scheduled to expire on September 29, 2026, but no additional tenders after the early deadline will be accepted as the aggregate amount tendered already meets the...
09-15 16:42
Dogfish Head Craft Brewery introduces its fall lineup, featuring seasonal beers and spirits. Highlights include Punkin Ale, a classic pumpkin beer, and the "Pass the Aux" variety pack with four fall-flavored beers. New offerings include XOCOLATL World Wide Stout, a rich Imperial Stout aged with cocoa nibs and spices, and Punkin Liqueur, crafted from Punkin Ale and aged in rum barrels. These seasonal beverages are perfect for autumn celebrations.
09-10 17:43
Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding $50,000 each to Parent Project Muscular Dystrophy (PPMD) in the U.S. and Duchenne Parent Project Netherlands. PPMD will focus on improving access to specialized care for underserved communities, particularly adults and those in rural areas, through multilingual resources and provider education. Duchenne Parent Project Netherlands will expand its early-interve...
09-10 11:00
As previously disclosed by Megan Holdings Limited (the "Company"), at the Annual General Meeting of Shareholders held on July 13, 2026, the Company’s shareholders approved the consolidation of the Company’s issued and unissued Class A Ordinary Shares and Class B Ordinary Shares at an aggregate ratio...
09-09 21:06
Remitly partners with Etsy to offer local payment options for new sellers in 15 countries. Starting this fall, Etsy sellers can choose Remitly as their payout provider, enabling them to hold earnings in USD, convert to local currencies, and deposit funds directly to bank accounts or mobile wallets. This marks Remitly's expansion into supporting small and medium businesses globally, building on its trusted cross-border payment network.
09-09 13:00
Cartesian Therapeutics granted inducement awards, including stock options, to three new employees on September 4, 2026. The options, totaling 59,700 shares with an exercise price of $9.27, vest over four years and have a ten-year term. The company, focused on cell therapy for autoimmune diseases, is advancing its lead asset, Descartes-08, in multiple clinical trials.
09-08 11:00